Search for: All records

The resurgence of oil and gas extraction in the Appalachian Basin has resulted in an excess of oil and gas brines in Pennsylvania, West Virginia, and Ohio. Primarily driven by unconventional development, this expansion has also impacted conventional wells and consequently, created economic pressure to develop effective and cheap disposal options. Using brine as a road treatment, directly or as a processed deicer, however, creates substantial concern that naturally occurring radioactive material in the brines can contaminate roads and road-side areas. Current decision making is based on risk exposure scenarios developed by regulatory agencies based on recreational users in rural areas and exposures to drivers during a typical commute. These scenarios are not appropriate for evaluating exposures to residential deicer users or people living near treated streets. More appropriate exposure scenarios were developed in this work and exposures predicted with these models based on laboratory measurements and literature data. Exposure scenarios currently used for regulatory assessment of brine road treatment result in predicted exposures of 0.4–0.6 mrem/year. Residential exposures predicted by the scenarios developed in this work are 4.6 mrem/year. If the maximum range of near-road soil radium concentrations observed in the region is used in this residential scenario (60 pCi/g²²⁶Ra, 50 pCi/g²²⁸Ra), residents living near these roads would be exposed to an estimated 296 mrems/year, above regulatory exposure thresholds used in nuclear facility siting assessments. These results underline the urgent need to clarify exposure risks from the use of oil and gas brines as a road treatment, particularly given the existing disparities in the distribution of road impacts across socioeconomic status.

Arsenic is a toxin, ranking first on the Agency for Toxic Substances and Disease Registry and the Environmental Protection Agency Priority List of Hazardous Substances. Chronic exposure increases the risk of a broad range of human illnesses, most notably cancer; however, there is significant variability in arsenic‐induced disease among exposed individuals. Human genetics is a known component, but it alone cannot account for the large inter‐individual variability in the presentation of arsenicosis symptoms. Each part of the gastrointestinal tract (GIT) may be considered as a unique environment with characteristic pH, oxygen concentration, and microbiome. Given the well‐established arsenic redox transformation activities of microorganisms, it is reasonable to imagine how the GIT microbiome composition variability among individuals could play a significant role in determining the fate, mobility and toxicity of arsenic, whether inhaled or ingested. This is a relatively new field of research that would benefit from early dialogue aimed at summarizing what is known and identifying reasonable research targets and concepts. Herein, we strive to initiate this dialogue by reviewing known aspects of microbe–arsenic interactions and placing it in the context of potential for influencing host exposure and health risks. We finish by considering future experimental approaches that might be of value.